Израел - иврит - Ministry of Health

sanofi - aventis israel ltd - spiramycin 1.5 miu - film coated tablets - spiramycin - respiratory tract infections, infections caused by clamydia, cryptosporidiosis pregnancy toxoplasmosis.

Израел - иврит - Ministry of Health

sanofi - aventis israel ltd - ofloxacin 200 mg - film coated tablets - ofloxacin - for the treatment of bacterial infections if these are due to ofloxacin sensitive pathogens.

Израел - иврит - Ministry of Health

sanofi - aventis israel ltd - teicoplanin - אבקה להכנת תמיסה לזריקה - teicoplanin 200 mg - teicoplanin - teicoplanin - for treatment of potentially serious gram-positive infections including those which cannot be treated with other antimicrobial drugs e.g.penicillins and cephalosporins.

Израел - иврит - Ministry of Health

sanofi - aventis israel ltd - metronidazole 250 mg - film coated tablets - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.

Израел - иврит - Ministry of Health

sanofi - aventis israel ltd - fludarabine phosphate 50 mg/vial - powder for solution for inj/inf - fludarabine - palliative treatment of patients with cll refractory to other therapy. treatment of less malignant non-hodgkin lymphoma of stage 3 to 4 in patients who have not responded to standard therapy with at least one alkylating agent or in whom the disease progressed during or after standard therapy. fludara is indicated for the initial treatment of patients with b- cell chronic lymphocytic leukaemia (cll) or after first line therapy, in patients with sufficient bone marrow reserves.

Израел - иврит - Ministry of Health

sanofi - aventis israel ltd - clofarabine 1 mg/ml - concentrate for solution for infusion - clofarabine - treatment of acute lymphoblastic leukaemia (all) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and who are about to undergo transplantation. safety and efficacy have been assessed in studies of patients < or = 21 years old at initial diagnosis .

Израел - иврит - Ministry of Health

abic marketing ltd - docetaxel 27.73 mg / 1 ml - concentrate and solvent for solution for infusion - docetaxel - breast cancerdocetaxel teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.docetaxel teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.docetaxel teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have inclu

Израел - иврит - Ministry of Health

sanofi - aventis israel ltd - lenograstim 33.6 miu/ml - lyophilized powder for injection - lenograstim - - reduction in duration of neutropenia and associated complications in patients undergoing bone marrow transplantation or cytotoxic chemotherapy associated with a febrile neutropenia. - autologous mobilization of peripheral blood progenitor cells. as an adjunct to allogenic mobilization of peripheral blood progenitor cells (pbpcs).

Израел - иврит - Ministry of Health

novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm

Израел - иврит - Ministry of Health

sanofi - aventis israel ltd - plerixafor 24 mg / 1.2 ml - solution for injection - plerixafor - mozobil is indicated in combination with g-csf to enhance mobilisation of haematopietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma .